SYRE

Spyre Therapeutics, Inc. (SYRE) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunology therapies for inflammatory bowel disease (IBD) and rheumatic diseases (RD). The company operates in a single segment and has no commercial product revenue, relying on equity financing and milestone payments from legacy asset sales.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue & Gains: The company recognized a $70.0 million gain on the sale of in-process research and development (IPR&D) assets for the six months ended June 30, 2026, compared to $10.0 million in the prior year. This was driven by FDA approval of pegzilarginase and the subsequent sale of the related Priority Review Voucher (PRV).
• Operating Expenses: R&D expenses increased by 54% year-over-year (YTD) to $125.9 million, driven by higher manufacturing and clinical trial costs for IBD and rheumatic disease programs. G&A expenses rose 32% due to increased headcount.
• Liquidity Position: Total cash, cash equivalents, and marketable securities increased significantly to $1.145 billion from $752.5 million at the end of 2025. This increase was primarily due to a $435.2 million net proceeds follow-on offering in April 2026 and a $296.4 million offering in October 2025.
• CVR Liability: The Contingent Value Rights (CVR) liability increased by $34.9 million YTD to $38.6 million, reflecting changes in fair value estimates and milestone achievements, partially offset by $22.9 million in payments to CVR holders.

Guidance, Outlook, and Risks

• Clinical Progress:
  • SKYLINE Trial (UC): Part A topline induction data for SPY001 and SPY002 were announced in April and June 2026, respectively, showing statistically significant reductions in histopathology scores. SPY003 data is expected in September 2026. Part B (combination arms) is currently enrolling.
  • SKYWAY Trial (RD): Enrollment for the Phase 2 basket trial of SPY072 in RA, PsA, and axSpA is complete. Topline data is expected in late 2026.
• Capital Resources: Management states the company has sufficient resources to fund operations for at least one year from the report date. However, additional financing will be required for future R&D and commercialization.
• Risks & Contingencies:
  • Regulatory & Clinical: Risks include failure of clinical trials, delays in regulatory approval, and potential adverse safety events.
  • Geopolitical & Supply Chain: The company faces risks related to the BIOSECURE Act and potential tariffs on pharmaceutical products, particularly regarding reliance on Chinese contract manufacturing organizations (CMOs) like WuXi Biologics.
  • Internal Controls: The company previously identified a material weakness in internal controls over financial reporting (Q4 2024) regarding EPS disclosures, which has been addressed with remediation measures.

Investor Verification Checklist

• Verify the sustainability of the $70 million IPR&D gain and confirm it is a non-recurring item not indicative of future operating performance.
• Monitor the burn rate given the 54% increase in R&D spend; confirm if the $1.1 billion liquidity runway is sufficient to reach Phase 3 data readouts without further dilution.
• Assess the impact of the BIOSECURE Act and new tariffs on the company's supply chain, specifically the transition away from Chinese CMOs.
• Review the SKYLINE Part B enrollment progress and regulatory feedback on combination arms, as this is critical for the company's "pipeline-in-a-product" strategy.
• Confirm the status of the CVR liability and potential future cash outflows to legacy stockholders.